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ABSTRACT
Objective: To assess the safety, tolerability and efficacy
of abatacept in patients with rheumatoid arthritis (RA)
who had failed anti-tumour necrosis factor (TNF) therapy
and were switched to abatacept directly or after
completing washout.
Methods: In this international, 6-month, open-label trial,
patients had active RA, an inadequate response to anti-
TNF therapy for 3 months or longer and a disease activity
score in 28 joints (DAS28 (C-reactive protein; CRP) of 5.1
or greater. ‘‘Washout’’ patients discontinued anti-TNF
therapy 2 months or longer pre-screening; ‘‘direct-switch’’
patients began abatacept (,10 mg/kg) at their next
scheduled anti-TNF therapy dose.
Results: 1046 patients were treated (449 washout, 597
direct-switch; baseline characteristics were similar
between groups). At 6 months, adverse events (AE;
78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and
discontinuations due to AE (3.8% vs 4.0%) and serious AE
(2.0% vs 1.3%) were comparable in washout versus
direct-switch patients. There were no opportunistic
infections. At 6 months, in washout versus direct-switch
patients, similar clinically meaningful improvements were
seen in DAS28 (CRP) (>1.2 unit improvement, 59.5% vs
53.6%, respectively; low disease activity state, 22.5% vs
22.3%; DAS28-defined remission, 12.0% vs 13.7%),
physical function (health assessment questionnaire dis-
ability index >0.22 improvement; 46.3% vs 47.1%) and
health-related quality of life (mean change in short-form
36 scores: physical component summary, 5.5 vs 6.1;
mental component summary, 4.8 vs 5.4).
Conclusion: Abatacept demonstrated acceptable safety
and tolerability and clinically meaningful efficacy over
6 months in patients with inadequate response to anti-
TNF therapy. Results were comparable with or without a
washout, supporting direct switching from anti-TNF
therapy to abatacept as an option in clinical practice.
Trial registration number: NCT00124982.
The efficacy and safety of abatacept, a selective T-
cell co-stimulation modulator, has been demon-
strated in patients with active rheumatoid arthritis
(RA) and an inadequate response to methotrexate
1
and/or anti-tumour necrosis factor (TNF) agents.
2
In the Abatacept Trial in Treatment of Anti-TNF
Inadequate Responders (ATTAIN) trial, patients
with an inadequate response to anti-TNF agents
were required to undergo a washout of their anti-
TNF therapy before initiating abatacept. To date,
no trial has evaluated abatacept treatment in
patients who have switched directly from anti-
TNF therapy without completing a washout
period. This option may be more relevant in
clinical practice.
The primary objective of the Abatacept
Researched in RA patients with an Inadequate
anti-TNF response to Validate Effectiveness
(ARRIVE) trial was to assess the safety and
tolerability of abatacept in patients with active
RA who had failed up to three anti-TNF agents.
Patients either completed a washout of their anti-
TNF therapy or switched directly to abatacept.
The ARRIVE trial included patients with RA who
are representative of those typically encountered in
clinical practice. Patients were eligible: (1) if they
had failed anti-TNF therapy for safety or toler-
ability reasons alone; (2) if they had a positive
purified protein derivative (PPD) test result (but
had initiated treatment for latent tuberculosis and
had a negative chest x ray); (3) irrespective of
which background non-biological disease-modify-
ing antirheumatic drug (DMARD) they were
receiving; or (4) if they were receiving abatacept
as monotherapy. (All patients who received abata-
cept as monotherapy were from the USA and were
treated in accordance with the prescribing infor-
mation for that country.) Here, we present the
results from the first 6 months of the ARRIVE
trial.
PATIENTS AND METHODS
Study population
Male and female patients with active RA
34aged
18 years or older were enrolled in the USA, the
European Union and Mexico. Patients were
required to have had an inadequate response of at
least 3 months to anti-TNF therapy, or to have
discontinued anti-TNF therapy for safety or toler-
ability reasons. Patients were required to have a
disease activity score in 28 joints (DAS28 (C-
reactive protein; CRP)) of 5.1 or greater and were
stratified into two groups according to anti-TNF
therapy use before enrollment. ‘‘Washout’’
patients had discontinued anti-TNF therapy
2 months or more before screening, whereas
‘‘direct-switch’’ patients had received anti-TNF
therapy within 2 months of screening, and
received abatacept on their next scheduled anti-
TNF therapy dose. Patients with an inadequate
response to multiple anti-TNF therapies were
included.
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history of disease associated with a major organ system, a
serious infection or active tuberculosis requiring treatment
within the past 3 years. Patients with a positive PPD test were
eligible for the study if they had initiated treatment for latent
tuberculosis one month or more before starting abatacept and
had a negative chest x ray at enrollment.
Study design
This was an international, phase IIIb, multicentre, open-label
study in which all patients received a fixed dose of abatacept
approximating 10 mg/kg on days 1, 15 and 29, and every
4 weeks thereafter up to and including day 141
(ClinicalTrials.gov identifier: NCT00124982).
5 This was a 6-
month trial with a long-term extension ending when the study
medication was marketed in each country.
At study entry, patients were classified, via the central
randomisation system, as ‘‘washout’’ if they had discontinued
biological therapy for 2 months or more; otherwise, they were
classified as ‘‘direct-switch’’. Each centre in the study recruited
patients for both treatment groups and enrollment was
controlled so that both current and previous users were
adequately represented.
Background non-biological DMARD were administered at the
same dose and regimen at the time of randomisation; dose
changes were not permitted unless for toxicity reasons. Before
enrollment, all background non-biological DMARD therapies
had to be stabilised for at least 28 days; oral corticosteroid
treatment was stabilised for at least 25 out of 28 days. No
biological DMARD therapies were allowed. Patients from the
USA were permitted to receive abatacept as monotherapy.
The study began on 10 April 2005 and ended on 10 January
2007. The study was conducted in accordance with the
Declaration of Helsinki and was approved by local institutional
review boards. All patients provided written informed consent.
Safety assessments
All patients who received at least one dose of study drug were
evaluated for adverse events (AE), serious AE, clinically relevant
changes in vital signs, laboratory test abnormalities and
tolerability of abatacept.
6
Efficacy assessments
Disease activity (DAS28 (CRP))
7 and physical function (health
assessment questionnaire disability index; HAQ-DI)
89 were
assessed on all visit days until day 169 or the early termination
visit. A clinically meaningful improvement in disease activity
was defined as a decrease from baseline of 1.2 or more units,
10 a
score 3.2 or less as low disease activity state (LDAS)
11 and less
than 2.6 as DAS28 (CRP)-defined remission.
12 13 A clinically
meaningful response in physical function was defined as an
improvement of 0.22 or more units.
14 The short-form 36 (SF-36)
measured health-related quality of life (HRQoL)
15 with assess-
ments made on visit days 1, 29, 85 and 169, or at the early
termination visit. An improvement of 3 or more units was
considered clinically meaningful.
15
Statistical analyses
The projected enrollment of 1000 treated patients allowed for
the detection of at least one case of an uncommon AE at a
frequency of 0.2%, with 86% probability. All available data from
all patients who received at least one infusion of the study
medication were included in the safety and efficacy datasets.
Subgroup prespecified analyses were performed to evaluate the
safety, tolerability and efficacy of abatacept in the washout
versus direct-switch groups.
For safety analyses, frequencies of AE, serious AE and
discontinuations due to AE/serious AE were summarised. For
efficacy analyses, mean changes and 95% CI are presented for
DAS28 (CRP), HAQ-DI and SF-36, based on patients with data
available at the visit of interest (as-observed). For responder
Figure 1 Patient disposition. TNF, tumour necrosis factor.
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ders), data are based on all patients, with those who
discontinued considered non-responders.
Post-hoc analyses were performed on the washout versus
direct-switch groups to assess infections on a monthly basis for
months 1, 2 and 3. Additional post-hoc analyses were performed
on the overall population to assess efficacy by: (1) last anti-TNF
agent used before the initiation of abatacept (etanercept,
infliximab or adalimumab); (2) number of previous anti-TNF
therapies (one, two or three); and (3) reason for anti-TNF
therapy failure (safety, tolerability or efficacy). This study was
not powered to detect differences in efficacy based on type,
number or reason for failure of previous anti-TNF therapy;
therefore, statistical testing was not performed.
RESULTS
Baseline patient demographics and disease characteristics
A total of 1286 patients were enrolled in the USA (103 sites), the
European Union (32 sites) and Mexico (two sites). Of these,
1046 were treated (842 USA, 197 Europe, seven Mexico), with
449 in the washout and 597 in the direct-switch group (fig 1).
Baseline patient demographics and disease characteristics
were similar for the washout and direct-switch groups
(table 1). Of the patients in the direct-switch group who
received infliximab before initiating abatacept, 16.3%, 29.7%,
28.5% and 25.6% had their last infliximab dose at less than 4,
less than 6, less than 8 and approximately 8 weeks, respectively,
before commencing abatacept. At enrollment, the mean number
(SD) of anti-TNF therapies used by washout and direct-switch
patients was 1.86 (0.97) and 1.95 (0.93), respectively. A total of
488 (46.7%), 340 (32.5%) and 200 (19.1%) patients had
previously received one, two or three previous anti-TNF
therapies (18 patients did not have available data). The most
frequent background non-biological DMARD in use on study
day 1 was methotrexate (table 1). Forty-three patients from the
USA (20/449 (4.5%) washout and 23/597 (3.9%) direct-switch
patients) were not receiving background non-biological
DMARD therapy during the 6-month study period and thus
received abatacept as monotherapy. (All patients who received
abatacept as monotherapy were from the USA and were
treated in accordance with the prescribing information for
that country.)
The mean (SD) duration of exposure to abatacept was similar
for washout and direct-switch patients (6.2 (1.0) and 6.1
(1.1) months, respectively); the mean (SD) number of infusions
was 6.4 (1.2) for both groups. Overall, 860 patients (82%)
completed 6 months of treatment, with similar proportions
among washout and direct-switch patients (fig 1). In the
washout and direct-switch patients, respectively, the main
reasons for discontinuation were lack of efficacy and AE (fig 1).
Table 1 Baseline demographics and disease characteristics by washout and direct-switch groups
Washout patients
(n = 449)
Direct-switch
patients
(n = 597)
Overall
(n = 1046)
Age, years 56.1 (12.5) 53.2 (12.3) 54.4 (12.4)
Weight, kg 78.9 (21.1) 79.1 (20.0) 79.0 (20.5)
Gender, female, n (%) 359 (80.0) 490 (82.1) 849 (81.2)
Race, n (%)
White 416 (92.7) 551 (92.3) 967 (92.4)
Black 27 (6.0) 33 (5.5) 60 (5.7)
Other 6 (1.3) 13 (2.2) 19 (1.8)
Duration of disease, years 13.0 (10.0) 10.6 (9.0) 11.6 (9.5)
Previous anti-TNF therapy*, n (%)
Etanercept 226 (50.3) 366 (61.3) 592 (56.6)
Infliximab 281 (62.6) 339 (56.8) 620 (59.3)
Adalimumab 193 (43.0) 309 (51.8) 502 (48.0)
Medications at day 1, n (%)
Methotrexate 307 (68.4) 423 (70.9) 730 (69.8)
Azathioprine 18 (4.0) 25 (4.2) 43 (4.1)
Gold 4 (0.9) 1 (0.2) 5 (0.5)
Hydroxychloroquine/chloroquine 71 (15.8) 86 (14.4) 157 (15.0)
Leflunomide 66 (14.7) 68 (11.4) 134 (12.8)
Sulfasalazine 32 (7.1) 60 (10.1) 92 (8.8)
Corticosteroids{ 280 (62.4) 331 (55.4) 611 (58.4)
Tender joints 17.8 (5.9) 17.8 (6.1) 17.8 (6.0)
Swollen joints 13.9 (5.6) 13.5 (5.4) 13.6 (5.5)
Patient global assessment, VAS 100 mm 72.7 (16.7) 73.1 (16.4) 72.9 (16.5)
HAQ-DI 1.7 (0.6) 1.7 (0.6) 1.7 (0.6)
DAS28 (CRP){ 6.2 (0.7) 6.2 (0.7) 6.2 (0.7)
CRP (mg/dl)1 2.2 (3.0) 2.1 (3.0) 2.1 (3.0)
Rheumatoid factor positive, n (%) 292 (65.0) 349 (58.5) 641 (61.3)
PPD positive, n (%) 9 (2.0) 17 (2.8) 26 (2.5)
Data are presented as mean (SD) unless otherwise indicated.
*Patients could have previously received more than one prior anti-tumour necrosis factor (TNF) therapy; two patients, one in the
washout and one in the direct-switch group, had received rituxmab more than 12 months before study entry.
{Oral and/or injectable.
{The joint count used was 28.
1The upper limit of normal for high sensitivity C-reactive protein (CRP) was 3.00 mg/l.
DAS28, disease activity score in 28 joints; HAQ-DI, health assessment questionnaire disability index; PPD, purified protein
derivative; VAS, visual analogue scale.
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A summary of safety to 6 months is presented in table 2. The
most frequent AE (occurring in >5% of patients in either group)
were upper respiratory tract infection, headache, nausea,
sinusitis, diarrhoea, bronchitis and fatigue. Serious AE occurred
in 10.4% of patients overall, and in a similar proportion of
patients in each group (11.1% and 9.9% of washout and direct-
switch patients, respectively). The most frequent serious AE
(excluding RA and osteoarthritis) were pneumonia (four direct-
switch patients, 0.7%) and bronchitis (two washout patients,
0.4%; and one direct-switch patient, 0.2%), invertebral disc
protrusion (three direct-switch patients, 0.5%) and myocardial
infarction (one washout patient, 0.2%; and two direct-switch
patients, 0.3%). There were two deaths: one caused by
congestive heart failure (a 54-year-old female washout patient
with a history of cardiomegaly and vascular congestion) and one
caused by cardiac arrest (a 67-year-old male direct-switch
patient with a history of hypertension).
Infusional reactions
Acute infusional reactions (within one hour of the start of
infusion) occurred in 20 (4.5%) washout patients and 37 (6.2%)
direct-switch patients, the most frequent of which were
dizziness (two washout and 10 direct-switch patients), head-
ache (two washout and 10 direct-switch patients), hyperten-
sion (five washout and two direct-switch patients), nausea
(one washout and eight direct-switch patients) and pruritis
(two washout and three direct-switch patients). One acute
infusional event was classified as severe (direct-switch group),
presenting as a rash requiring treatment and leading to drug
discontinuation.
Infections
Overall, infections were reported in 38.9% of patients (39.2% and
38.7%washoutanddirect-switchpatients, respectively),the most
frequent of which were upper respiratory tract infection (8.9%
and 7.4% of washout and direct-switch patients, respectively),
sinusitis (6.2% and 6.0% of washout and direct-switch patients,
respectively) and bronchitis (5.6% and 3.7% of washout and
direct-switch patients, respectively). The frequency of serious
infections was similar between groups, at 2.7% and 2.2%
among washout and direct-switch patients, respectively
(table 2). No other serious infection occurred in more than
one patient in the study. No cases of opportunistic infections,
including tuberculosis, were reported in either group.
Frequencies of infections by month were comparable for
washout and direct-switch patients (11.1% vs 11.4% in month
1, 8.2% vs 10.4% in month 2 and 7.8% vs 6.4% in month 3,
respectively). Overall, the frequencies of serious infections
during months 1, 2 and 3 were 0.4%, 0.6% and 0.7%,
respectively; for washout and direct-switch patients, frequen-
cies were 0% versus 0.7% in month 1, 0.9% versus 0.3% in
month 2 and 1.1% versus 0.3% in month 3, respectively.
Neoplasms
There were four (0.9%) neoplasms reported in the washout
compared with two (0.3%) in the direct-switch group (table 2).
There were four reports of non-skin malignancies (all in
washout patients), including two patients with breast cancer,
one with lung adenocarcinoma and one with uterine cancer
(table 2).
Autoimmune disorders
The frequency of autoimmune disorders was slightly higher in
the direct-switch compared with the washout group (nine
patients (1.5%) vs four patients (0.9%), respectively). The most
commonly occurring autoimmune disorder was psoriasis (one
mild and one moderate case in washout patients; two mild cases
in direct-switch patients). Three of these cases were new onset,
whereas one patient had a history of psoriasis. All other types of
autoimmune disorders were reported in no more than two
patients across groups, were not severe and comprised:
erythema nodosum, Sjogren’s syndrome, sicca syndrome,
autoimmune thyroiditis (all two patients each) and keratocon-
junctivitis sicca (one patient).
Table 2 Safety summary at 6 months for washout and direct-switch patients
Patients with AE, n (%)
Washout patients
(n = 449)
Direct-switch
patients
(n = 597)
Overall
(N = 1046)
Total patients with AE 350 (78.0) 473 (79.2) 823 (78.7)
Total infections 176 (39.2) 231 (38.7) 407 (38.9)
Discontinuations due to AE 17 (3.8) 24 (4.0) 41 (3.9)
Serious AE 50 (11.1) 59 (9.9) 109 (10.4)
Total serious infections 12 (2.7) 13 (2.2) 25 (2.4)
Most frequent serious infections
Pneumonia* 0 4 (0.7) 4 (0.4)
Bronchitis* 2 (0.4) 1 (0.2) 3 (0.3)
Lobar pneumonia* 2 (0.4) 0 2 (0.2)
Discontinuations due to serious AE 9 (2.0) 8 (1.3) 17 (1.6)
Autoimmune disorders 4 (0.9) 9 (1.5) 13 (1.2)
Total neoplasms{ 8 (1.8) 7 (1.2) 15 (1.4)
Total malignancies 4 (0.9) 2 (0.3) 6 (0.6)
Basal cell carcinoma 0 2 (0.3) 2 (0.2)
Breast cancer 2 (0.4) 0 2 (0.2)
Lung adenocarcinoma 1 (0.2) 0 1 (0.1)
Uterine cancer 1 (0.2) 0 1 (0.1)
*Most frequent serious infections, reported in more than one patient in the overall population; all others occurred in one patient or
fewer overall.
{Benign, malignant and unspecified.
AE, adverse event.
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Clinical efficacy
At 6 months, the improvements in efficacy observed with
abatacept were similar in washout and direct-switch patients
(fig 2). The mean reduction (SE) in DAS28 from baseline was
22.0 (0.1) in both washout and direct-switch patients (fig 2A).
Clinically meaningful improvements in DAS28 were reported in
56.1% of patients overall and in 59.5% and 53.6% of washout
and direct-switch patients, respectively.
Overall, 22.4% of patients achieved LDAS and 13.0% achieved
remission, including 22.5% and 12.0% of washout patients and
22.3% and 13.7% of direct-switch patients, respectively (fig 2B).
Post-hoc analyses of the mean change from baseline in DAS28
and the proportions of patients achieving LDAS and remission
at 6 months were generally similar, regardless of the type of
previous anti-TNF agent used (etanercept, infliximab or
adalimumab) or the reason for the failure of previous anti-
TNF therapy (ie, safety/tolerability versus efficacy). For the
DAS28 mean change from baseline, LDAS or remission, the 95%
CI did not overlap for patients who had failed one or three
previous anti-TNF therapies (table 3).
HRQoL and physical function
Clinically meaningful improvements in physical function
(HAQ-DI responses) were observed in 46.7% of the overall
population and 46.3% and 47.1% of washout and direct-switch
patients, respectively. Improvements in HRQoL are presented in
fig 3.
Monotherapy patients
Safety
Forty-three patients (20 washout and 23 direct-switch patients)
received abatacept as monotherapy. AE and serious AE were
reported in 83.7% and 9.3% patients overall, with 80.0% versus
87.0% and 5.0% versus 13.0% in washout versus direct-switch
patients, respectively. One patient in the washout group
discontinued because of an AE, no patients discontinued
because of a serious AE. Serious infections were reported in
one patient (gastroenteritis salmonella) from the direct-switch
group only.
Efficacy
Efficacy in the patients receiving monotherapy was comparable
to that seen in patients receiving background DMARD. For the
overall, washout and direct-switch groups, respectively, mean
improvements (SE) in DAS28 were 1.84 (0.19), 1.61 (0.25) and
2.05 (0.28); the percentages of patients with a clinically
meaningful improvement in DAS28 (95% CI) were 48.8%
(33.9 to 63.8), 50.0% (28.1 to 71.9) and 47.8% (27.4 to 68.2);
mean changes (SE) in HAQ-DI were 20.38 (0.10), 20.29 (0.16)
and 20.46 (0.13); mean changes (SE) in PCS were 4.80 (1.13),
3.65 (1.74) and 5.80 (1.47) and mean changes (SE) in MCS were
7.34 (1.93), 7.13 (2.38) and 7.53 (3.03).
DISCUSSION
The 6-month results of this study in abatacept-treated patients
with RA and an inadequate response to anti-TNF therapy
demonstrate acceptable safety and tolerability and clinically
meaningful improvements in efficacy. Results were comparable
in patients who had completed a washout of their anti-TNF
therapy and in patients who switched directly to abatacept.
These results confirm and extend previous findings from the
ATTAIN study, which evaluated a similar patient population.
2
Of the 391 patients in the ATTAIN study who responded
inadequately to anti-TNF therapy, significantly more abatacept-
treated patients achieved American College of Rheumatology
(ACR)20 (primary endpoint), ACR50 and ACR70 responses
compared with placebo (50.4%, 20.3% and 10.2% vs 19.5%,
3.8% and 1.5%, respectively).
2 The ARRIVE study evaluated a
larger population of 1046 patients, and included a substantially
higher proportion of patients who had previously tried
adalimumab compared with the ATTAIN study (51% vs 2%,
respectively) as a result of the more widespread use of this anti-
TNF agent at the time of enrollment. The ARRIVE study,
unlike the ATTAIN trial, included patients who had failed anti-
TNF therapy because of lack of efficacy, safety or tolerability
reasons alone. Patients were also able to receive abatacept if
they had a positive PPD test result, providing they had received
one month or more of treatment for latent tuberculosis and had
a negative chest x ray. Patients were not limited to particular
background non-biological DMARD, and patients from the USA
Figure 2 Efficacy following 6 months of abatacept treatment in
washout and direct-switch patients. (A) Mean improvements in disease
activity score in 28 joints (DAS28 (C-reactive protein; CRP));
(B) Percentage of patients achieving low disease activity state (LDAS;
DAS28 (CRP) (3.2) and DAS28-defined remission (DAS28 (CRP) ,2.6).
Error bars represent 95% CI.
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background DMARD. Patients included in the ARRIVE study
exhibited levels of baseline RA disease activity closer to those
commonly encountered in daily practice, with lower mean
swollen and tender joint counts.
121 6Importantly, upon disconti-
nuation of their anti-TNF treatment, patients were able to switch
directly to abatacept on their next scheduled anti-TNF dose and
were not required to undergo a washout.
In the ARRIVE study, the safety profile of abatacept was
unaffected by a lack of washout period for anti-TNF agents
before initiating abatacept. No increase in the overall frequency
of infection was seen in patients switching directly to abatacept
compared with those who completed a washout. Furthermore,
incidences of infectious events in washout patients were
comparable to those observed in direct-switch patients when
assessed monthly after the initiation of abatacept therapy.
There was a slightly higher frequency of infection in the first
month of the study, regardless of whether or not patients
completed a washout period. Despite the inclusion of patients
testing positive for PPD, there were no cases of tuberculosis
Table 3 DAS28 responses at 6 months of abatacept treatment in patients stratified by number of previous
anti-TNF agents, previous anti-TNF agent and reason for failure of previous anti-TNF agent
Patient subgroup
DAS28 response at 6 months (95% CI)
DAS28 mean change
from baseline
LDAS
% responders
DAS28-defined
remission
% responders
Type of previous anti-TNF*
Etanercept (n = 278) 22.0 (22.2 to 21.8) 24.1 (19.1 to 29.1) 14.7 (10.6 to 18.9)
Infliximab (n = 348) 22.1 (22.3 to 22.0) 21.3 (17.0 to 25.6) 14.1 (10.4 to 17.7)
Adalimumab (n = 351) 21.9 (22.1 to 21.8) 23.4 (18.9 to 27.8) 11.1 (7.8 to 14.4)
No of previous anti-TNF{
1 (n = 488) 22.1 (22.2 to 22.0) 24.8 (21.0 to 28.6) 15.8 (12.5 to 19.0)
2 (n = 340) 22.1 (22.3 to 21.9) 22.9 (18.5 to 27.4) 12.9 (9.4 to 16.5)
>2 (n = 540) 22.0 (22.1 to 21.8) 20.0 (16.6 to 23.4) 10.6 (8.0 to 13.1)
3 (n = 200) 21.7 (21.9 to 21.5) 15.0 (10.1 to 19.9) 6.5 (3.1 to 9.9)
Reason for failure{
Safety (n = 106) 22.3 (22.6 to 22.0) 30.2 (21.4 to 38.9) 16.0 (9.1 to 23.0)
Intolerability (n = 230) 22.2 (22.4 to 22.0) 22.6 (17.2 to 28.0) 13.5 (9.1 to 17.9)
Safety or intolerability (n = 305) 22.2 (22.4 to 22.0) 25.6 (20.7 to 30.5) 14.4 (10.5 to 18.4)
Efficacy (n = 952) 22.0 (22.1 to 21.9) 20.9 (18.3 to 23.5) 12.2 (10.1 to 14.3)
n Numbers are based on patients with available data (as-observed population).
*Data were unavailable for 69 patients and are presented for the last anti-tumour necrosis factor (TNF) therapy received before
initiating abatacept.
{Data were unavailable for 18 patients.
{Patients could have failed for more than one reason.
DAS28, disease activity score in 28 joints; LDAS, low disease activity state.
Figure 3 Effect of abatacept treatment on health-related quality of life (short-form 36 (SF-36) component scores and individual measures) in washout
and direct-switch patients, following 6 months of abatacept treatment. Error bars represent 95% CI. A change in score of 3 or more was considered
clinically meaningful (shown as dotted line). MCS, mental component summary; PCS, physical component summary.
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occurred. Four non-skin malignancies were reported in 1046
patients treated with abatacept: the use of large databases, such
as RA registries, and also integrated analyses of existing trial
data, will assist in the continued monitoring of rare events, such
as malignancies. Autoimmune events occurred in less than 2%
of patients, at a slightly higher frequency in direct-switch
than washout patients. As direct switching to abatacept from
anti-TNF therapy did not lead to an increase in AE, including
infections, this study provides support for direct switching to
abatacept in patients who have an inadequate response to anti-
TNF therapy.
Consistent with previous findings in anti-TNF therapy
inadequate responders,
2 clinically meaningful improvements in
disease activity, physical function and HRQoL were seen
following abatacept treatment in the ARRIVE study. The
efficacy of abatacept was similar in patients who had completed
a washout of their anti-TNF therapy and in those who switched
directly to abatacept. The efficacy of abatacept monotherapy
was comparable to that observed in patients receiving back-
ground DMARD, although it should be noted that patient
numbers were low in the former subgroup.
Abatacept provided considerable efficacy benefits irrespective
of previous anti-TNF therapy experience, but the magnitude of
improvement was greater in patients who had previously tried
only one anti-TNF agent. Meaningful improvements in clinical
measures of efficacy and HRQoL were observed in patients who
had failed their previous anti-TNF therapy as a result of efficacy,
tolerability or safety reasons; improvements were greater in
patients who were safety failures. A previously published
analysis of patients from the ATTAIN trial
17 demonstrated
that abatacept is efficacious regardless of whether patients did
not respond to anti-TNF therapy or lost their response to anti-
TNF therapy over time.
These data must be interpreted within the context of several
limitations. The treatment period was limited to 6 months,
potentially restricting the capacity to detect opportunistic
infections and other infrequent AE. As the sample size for this
study was not determined to detect differences between
washout and direct-switch patients, the power for testing
differences between these groups is unknown. However, as
baseline demographics and disease characteristics were compar-
able, it is appropriate to compare the safety and efficacy
between the two groups. Compared with results obtained from
randomised clinical trials, the open-label nature of the trial
design may introduce bias due to patient and/or investigator
preconceptions. In addition, although this trial included
patients with lower baseline disease activity than is often seen
in randomised clinical trials, patients still had moderate-to-
severe active RA, having failed one or more anti-TNF agent.
These patients may represent a population with higher disease
activity observed in daily clinical practice.
In conclusion, these results demonstrate the acceptable safety
and tolerability and clinically meaningful efficacy benefits of
abatacept in patients with an inadequate response to anti-TNF
therapy, a population representative of those encountered in
clinical practice. Moreover, these results support the clinical use
of direct switching to abatacept from anti-TNF agents in
patients who do not respond to, lose response to, or are unable
to tolerate anti-TNF agents.
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